Tumstatin induces apoptosis mediated by Fas signaling pathway in oral squamous cell carcinoma SCC-VII cells

Hwang‑Bo,Jeon; Park,Jong‑Hwa; Chung,In  Sik

doi:10.3892/ol.2015.3261

Tumstatin induces apoptosis mediated by Fas signaling pathway in oral squamous cell carcinoma SCC-VII cells

Authors:
- Jeon Hwang‑Bo
- Jong‑Hwa Park
- In Sik Chung
View Affiliations

Affiliations: Department of Genetic Engineering and Graduate School of Biotechnology, Kyung Hee University, Yongin, Gyeonggi 446‑701, Republic of Korea
Published online on: May 25, 2015 https://doi.org/10.3892/ol.2015.3261
Pages: 1016-1022

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oral squamous cell carcinoma is a cancer originating in the tissues lining the mouth and lips. The present study investigated the effects of recombinant tumstatin, an anti‑angiogenic agent with distinct antitumor activity, on oral squamous cell carcinoma SCC-VII cells. Apoptosis was characterized by YO-PRO-1 staining, sub-G1 population, and DNA fragmentation analysis. Apoptotic mechanism of tumstatin was also investigated. The antitumor activity of tumstatin was further evaluated using an SCC-VII animal model. Recombinant tumstatin was found to decrease the viability of SCC‑VII cells in a dose‑dependent manner. The number of cells stained with the apoptotic marker YO‑PRO‑1, the sub‑G1 cell population and the level of apoptotic DNA fragmentation increased in the SCC‑VII cells following treatment with recombinant tumstatin. In addition, recombinant tumstatin treatment increased the expression of the Fas gene at the transcript and protein levels, and the inhibition of cell viability by recombinant tumstatin was suppressed by a neutralizing anti‑Fas antibody. Furthermore, treatment with recombinant tumstatin decreased the volume and weight of tumors in C3H/HeJ mice implanted with SCC‑VII cells. In conclusion, the results indicated that tumstatin induced apoptosis that is mediated by the Fas signaling pathway in SCC‑VII cells and inhibited tumor growth in an SCC-VII animal model.

View Figures

View References

1	Koch WM, Stafford E and Bajaj G: Cancer of the oral cavity. Part A: General principles and managementHead and neck cancer: A multidisciplinary approach. Harrison LB, Sessions RB and Hong WK: 3rd. Lippincott Williams and Wilkins; Philadelphia, PA: pp. 250–265. 2009
2	Feller L and Lemmer J: Oral squamous cell carcinoma: Epidemiology, clinical presentation and treatment. J Cancer Ther. 3:263–268. 2012. View Article : Google Scholar
3	Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y and Jacobson MD: Programmed cell death and the control of cell survival: Lessons from the nervous system. Science. 262:695–700. 1993. View Article : Google Scholar : PubMed/NCBI
4	Wyllie AH, Kerr JF and Currie AR: Cell death: The significance of apoptosis. Int Rev Cytol. 68:251–306. 1980.PubMed/NCBI
5	Kaufmann SH and Earnshaw WC: Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 256:42–49. 2000. View Article : Google Scholar : PubMed/NCBI
6	King KL and Cidlowski JA: Cell cycle regulation and apoptosis. Annu Rev Physiol. 60:601–617. 1998. View Article : Google Scholar : PubMed/NCBI
7	Boedefeld WM 2nd, Bland KI and Heslin MJ: Recent insights into angiogenesis, apoptosis, invasion and metastasis in colorectal carcinoma. Ann Surg Oncol. 10:839–851. 2003. View Article : Google Scholar : PubMed/NCBI
8	Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE and Kalluri R: Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem. 275:21340–21348. 2000. View Article : Google Scholar : PubMed/NCBI
9	Hamano Y and Kalluri R: Tumstatin, the NC1 domain of α3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys Res Commun. 333:292–298. 2005. View Article : Google Scholar : PubMed/NCBI
10	Pasco S, Brassart B, Ramont L, Maquart FX and Monboisse JC: Control of melanoma cell invasion by type IV collagen. Cancer Detect Prev. 29:260–266. 2005. View Article : Google Scholar : PubMed/NCBI
11	Pasco S, Ramont L, Venteo L, Pluot M, Maquart FX and Monboisse JC: n vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model. Exp Cell Res. 301:251–265. 2004. View Article : Google Scholar : PubMed/NCBI
12	Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ, Bergers G and Pieper RO: The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells n vitro and n vivo. Cancer Res. 66:11331–11340. 2006. View Article : Google Scholar : PubMed/NCBI
13	Chung IS, Son YI, Ko YJ, Baek CH, Cho JK and Jeong HS: Peritumor injections of purified tumstatin delay tumor growth and lymphatic metastasis in an orthotopic oral squamous cell carcinoma model. Oral Oncol. 44:1118–1126. 2008. View Article : Google Scholar : PubMed/NCBI
14	Jeon HK, Chang KH, Kim KI and Chung IS: Functional expression of recombinant tumstatin in stably transformed Drosophila melanogaster S2 cells. Biotechnol Lett. 25:185–189. 2003. View Article : Google Scholar : PubMed/NCBI
15	Alessandri G, Filippeschi S, Sinibaldi P, Mornet F, Passera P, Spreafico F, Cappa PM and Gullino PM: Influence of gangliosides on primary and metastatic neoplastic growth in human and murine cells. Cancer Res. 47:4243–4247. 1987.PubMed/NCBI
16	Maeshima Y, Colorado PC and Kalluri R: Two RGD-independent alpha v beta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem. 275:23745–23750. 2000. View Article : Google Scholar : PubMed/NCBI
17	Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N, Hynes RO and Kalluri R: Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science. 295:140–143. 2002. View Article : Google Scholar : PubMed/NCBI
18	Maeshima Y, Yerramalla UL, Dhanabal M, et al: Extracellular matrix-derived peptide binds to alpha(v)beta (3) integrin and inhibits angiogenesis. J Biol Chem. 276:31959–31968. 2001. View Article : Google Scholar : PubMed/NCBI
19	Monboisse JC, Garnotel R, Bellon G, Ohno N, Perreau C, Borel JP and Kefalides NA: The alpha 3 chain of type IV collagen prevents activation of human polymorphonuclear leukocytes. J Biol Chem. 269:25475–25482. 1994.PubMed/NCBI
20	Li YJ, Sun LC, He Y, Liu XH, Liu M, Wang QM and Jin XM: The anti-tumor properties of two tumstatin peptide fragments in human gastric carcinoma. Acta Pharmacol Sin. 30:1307–1315. 2009. View Article : Google Scholar : PubMed/NCBI
21	Liu Y, Li J, Xu H, Zhang Y, Liu Y and Liu X: Mitochondria-mediated tumstatin peptide-induced HepG2 cell apoptosis. Int J Mol Med. 24:653–659. 2009. View Article : Google Scholar : PubMed/NCBI
22	López-Hernández FJ, Ortiz MA and Piedrafita FJ: The extrinsic and intrinsic apoptotic pathways are differentially affected by temperature upstream of mitochondrial damage. Apoptosis. 11:1339–1347. 2006. View Article : Google Scholar : PubMed/NCBI
23	Yin XM: Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res. 10:161–167. 2000. View Article : Google Scholar : PubMed/NCBI
24	Maeshima Y, Manfredi M, Reimer C, Holthaus KA, Hopfer H, Chandamuri BR, Kharbanda S and Kalluri R: Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem. 276:15240–15248. 2001. View Article : Google Scholar : PubMed/NCBI
25	Oliveira-Ferrer L, Wellbrock J, Bartsch U, Penas EM, Hauschild J, Klokow M, Bokemeyer C, Fiedler W and Schuch G: Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway. Mol Cancer. 12:1442013. View Article : Google Scholar : PubMed/NCBI